Module 3: How initial localized PC treatment choice impacts later treatment options
Primary Audience:
This activity is intended to meet the educational needs of urologists, medical oncologists and radiation oncologists involved in the care of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).
This module will cover how initial treatment choice for localized prostate cancer (radical prostatectomy or radiotherapy) affects availability and efficacy of later treatment options.
Catherine Handy Marshall, MD, MPH
Assistant Professor of Oncology
Internal Medicine, Oncology
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Catherine Marshall is an Assistant Professor in the Department of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include internal medicine and oncology.
She received her M.D. and M.P.H. from Johns Hopkins, where she also completed her residency and an oncology fellowship.
1.
Develop a deeper understanding of the impact of initial treatment choice on subsequent treatment options for patients with high-risk nmHSPC.
